Spots Global Cancer Trial Database for Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
Official Title: Pilot Study of a Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
Study ID: NCT05950139
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Johns Hopkins University, Baltimore, Maryland, United States
Contact Details
Name: Vincent Lam, MD
Affiliation: Johns Hopkins University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
